Free Trial
NASDAQ:ACTU

Actuate Therapeutics (ACTU) Stock Price, News & Analysis

Actuate Therapeutics logo
$8.44 +0.22 (+2.68%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$8.45 +0.01 (+0.12%)
As of 08/29/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Actuate Therapeutics Stock (NASDAQ:ACTU)

Key Stats

Today's Range
$8.02
$8.55
50-Day Range
$5.66
$8.67
52-Week Range
$5.47
$11.99
Volume
41,064 shs
Average Volume
55,980 shs
Market Capitalization
$175.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.33
Consensus Rating
Buy

Company Overview

Receive ACTU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Actuate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ACTU Stock News Headlines

Q3 Earnings Forecast for ACTU Issued By B. Riley
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.tc pixel
Actuate Therapeutics (NASDAQ:ACTU) Cut to "Sell" at Wall Street Zen
See More Headlines

ACTU Stock Analysis - Frequently Asked Questions

Actuate Therapeutics' stock was trading at $7.96 at the start of the year. Since then, ACTU shares have increased by 6.0% and is now trading at $8.44.

Actuate Therapeutics, Inc. (NASDAQ:ACTU) announced its earnings results on Thursday, August, 14th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.11.

Actuate Therapeutics (ACTU) raised $27 million in an initial public offering on Tuesday, August 13th 2024. The company issued 3,000,000 shares at a price of $8.00-$10.00 per share. Titan Partners acted as the underwriter for the IPO and Newbridge Securities Corp. was co-manager.

Actuate Therapeutics' top institutional investors include BIOS Capital Management LP (48.68%), Voss Capital LP (1.40%), Geode Capital Management LLC (0.58%) and Gleason Group Inc. (0.10%). Insiders that own company stock include Todd S Thomson, Leslie W Kreis, Equity Cof Lp Bios and Aaron GL Fletcher.
View institutional ownership trends
.

Shares of ACTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Actuate Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Aileron Therapeutics (ALRN), Amgen (AMGN) and AstraZeneca (AZN).

Company Calendar

Last Earnings
8/14/2025
Today
8/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ACTU
Previous Symbol
NASDAQ:ACTU
CIK
1652935
Web
N/A
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

High Price Target
$21.00
Low Price Target
$20.00
Potential Upside/Downside
+140.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$27.28 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-281.83%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.73
Quick Ratio
0.73

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.13) per share
Price / Book
-64.92

Miscellaneous

Outstanding Shares
20,750,000
Free Float
6,360,000
Market Cap
$175.13 million
Optionable
N/A
Beta
N/A

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:ACTU) was last updated on 8/30/2025 by MarketBeat.com Staff
From Our Partners